First clinical study started with BAN2401

BAN2401 is a novel antibody targeting the neurotoxin believed to cause Alzheimer s disease and developed by BioArctic Neuroscience.

The primary goal of the study is to determine the safe dose range of BAN2401 and its effect on Alzheimer biomarkers. More than 80 Alzheimer´s patients with mild to moderate forms of the disease will participate. BAN2401 is the first monoclonal antibody to selectively bind and efficiently eliminate amyloid- protofibrils, the toxic protein believed to cause Alzheimer´s disease.